EP2 antagonists as novel anti-epileptogenic agents
EP2 antagonists as novel anti-epileptogenic agents
批准号:
10026712
负责人:
Thota Ganesh
金额:
$38.93万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-12-15 至 2020-11-30
关键词:
AcuteAdultAftercareAlbuminsAnimal ModelAnimalsAnti-Inflammatory AgentsAntiepileptogenicAstrocytesAtrophicBehavioralBlood - brain barrier anatomyBrainBrain InjuriesChronicCraniocerebral TraumaCytokine ActivationDevelopmentDiagnosisDinoprostoneDoseDrug KineticsElectrocorticogramEpilepsyEpileptogenesisExcipientsFormulationFrequenciesFunctional disorderFutureGenerationsGliosisGoalsHalf-LifeHippocampus (Brain)IncidenceInfiltrationInflammationInflammatoryInflammatory ResponseIsoflurophateLeukocytesMeasuresMediatingMediator of activation proteinMicrogliaModelingMorbidity - disease rateMusNeocortexNerve DegenerationNeuronsOralPTGS2 genePatientsPharmaceutical PreparationsPharmacology StudyPhasePilocarpinePlasmaPlasma EnhancementPlayPost-Traumatic EpilepsyPre-Clinical ModelPrevention therapyPropertyProsencephalonProstaglandin E ReceptorProstaglandinsRattusRecurrenceRiskRodent ModelRouteSafetySeizuresStatus EpilepticusSynapsesTestingTherapeuticTherapeutic AgentsTimeTissuesTraumatic Brain InjuryUnited Statesblood-brain barrier permeabilizationcontrolled releasecostfluid percussion injuryin vivoinflammatory markerintraperitoneallead optimizationmortalityneuron lossneuropathologynovelpreventreceptorsmall moleculesubcutaneoustreatment effect
中文摘要
癫痫与显著的死亡率和发病率相关,估计美国每年的成本为150亿美元。
在美国,每年约有15万例新的癫痫病例被诊断出来。抗癫痫药物,
癫痫病人的癫痫发作,并不能阻止癫痫的发展。创伤后癫痫(PTE)发生在患者
创伤性脑损伤(TBI)。成人穿透性TBI后癫痫的发病率约为50%。照经上所
非常重要的是鉴定新的辅助治疗剂,其可以与抗癫痫药物一起沿着给药,
延缓PTE和其他类型癫痫的进展并预防其发展。
在TBI和癫痫发作后的患者和啮齿动物模型的脑中发现了考克斯-2和PGE 2的诱导。最近我们
已经表明,限制于前脑神经元的考克斯-2缺失在毛卡普林诱导的状态模型中是有益的
癫痫(SE)。PGE 2受体EP 2的选择性拮抗剂重现了条件性考克斯-2缺失的许多特征
在SE模型中,通过钝化几种促炎介质、神经胶质增生和神经变性,提示大多数
脑损伤模型中考克斯-2的促炎作用是通过EP 2受体介导的。因此,我们假设,
以考克斯-2下游的EP 2受体为靶点,将是开发抗癫痫药物的上级策略
疗法在这项研究中,我们提出了一个概念验证,是否靶向EP 2受体的小分子
拮抗剂在大鼠头侧沟旁液压冲击损伤(rpFPI)模型中具有抗癫痫作用。
癫痫
英文摘要
Epilepsy is associated with significant mortality and morbidity, with an estimated annual cost of $15 billion to the USA.
About 150,000 new cases of epilepsy are diagnosed in the United States each year. The anti-seizure drugs, which blunt
seizures in epilepsy patients, do not prevent the development of epilepsy. Posttraumatic epilepsy (PTE) arises in patients
due to traumatic brain injury (TBI). The incidence of epilepsy in adults after a penetrating TBI is about 50%. Thus, it is
very important to identify novel adjunct therapeutic agents which can be administered along with anti-seizure drugs to
delay the progression and prevent the development of PTE and other types of epilepsy.
Induction of COX-2 and PGE2 were found in the brain of patients and rodent models after TBI and seizures. Recently, we
have shown that COX-2 deletion restricted to forebrain neurons is beneficial in pilocaprine induced model of status
epilepticus (SE). A selective antagonist of PGE2 receptor EP2 recapitulated many features of conditional COX-2 deletion
in SE model by blunting several proinflammatory mediators, gliosis and neurodegeneration, suggesting that most of the
COX-2 proinflammatory effects are mediated through EP2 receptor in a brain injury model. Thus, we hypothesized that
targeting EP2 receptor, downstream of COX-2, will be a superior strategy for the development of anti-epileptogenic
therapy. In this study, we propose to test a proof-of-concept whether targeting EP2 receptor with small molecule
antagonist will be anti-epileptogenic in rat rostral parasagittal fluid percussion injury (rpFPI) model of posttraumatic
epilepsy.
期刊论文(11)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.biopha.2022.112646
发表时间:
2022-03
期刊:
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
影响因子:
--
作者:
[Rawat V, Banik A, Amaradhi R, Rojas A, Taval S, Nagy T, Dingledine R, Ganesh T]
通讯作者:
Ganesh T
DOI:
10.1021/acs.molpharmaceut.8b00764
发表时间:
2018-12-03
期刊:
Molecular pharmaceutics
影响因子:
4.9
作者:
[Ganesh T, Banik A, Dingledine R, Wang W, Amaradhi R]
通讯作者:
Amaradhi R
DOI:
10.1021/acs.jmedchem.3c00655
发表时间:
2023-07-27
期刊:
JOURNAL OF MEDICINAL CHEMISTRY
影响因子:
7.3
作者:
[Ganesh, Thota]
通讯作者:
Ganesh, Thota
A Novel Second-Generation EP2 Receptor Antagonist Reduces Neuroinflammation and Gliosis After Status Epilepticus in Rats.
新型第二代 EP2 受体拮抗剂可减少大鼠癫痫持续状态后的神经炎症和神经胶质增生。
DOI:
10.1007/s13311-020-00969-5
发表时间:
2021
期刊:
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
影响因子:
--
作者:
[Rojas,Asheebo, Amaradhi,Radhika, Banik,Avijit, Jiang,Chunxiang, Abreu-Melon,JuanMartin, Wang,Sarah, Dingledine,Raymond, Ganesh,Thota]
通讯作者:
Ganesh,Thota
DOI:
10.1016/j.bmc.2020.115830
发表时间:
2020-12-15
期刊:
Bioorganic & medicinal chemistry
影响因子:
3.5
作者:
[Motati DR, Amaradhi R, Ganesh T]
通讯作者:
Ganesh T
EP2 antagonists as novel anti-epileptogenic agents
-
批准号:9456366
-
项目类别:
-
资助金额:$40.37万
-
财政年份:2017
-
负责人:Thota Ganesh
-
依托单位:
Development of EP2 receptor antagonists for suppression of Alzheimer's neuropathology
-
批准号:9645890
-
项目类别:
-
资助金额:$8.3万
-
财政年份:2016
-
负责人:Thota Ganesh
-
依托单位:
Development of EP2 receptor antagonists for suppression of Alzheimer's neuropathology
-
批准号:9756261
-
项目类别:
-
资助金额:$70.27万
-
财政年份:2016
-
负责人:Thota Ganesh
-
依托单位:
Development of EP2 receptor antagonists for suppression of Alzheimer's neuropathology
-
批准号:9240161
-
项目类别:
-
资助金额:$75.81万
-
财政年份:2016
-
负责人:Thota Ganesh
-
依托单位:
海外基金